Article Information
History
- November 10, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Cynthia Portal-Celhay, MD1,*,
- Eduardo Forleo-Neto, MD1,
- Will Eagan, PhD1,
- Bret J Musser, PhD1,
- John D Davis, PhD1,
- Kenneth C Turner, PhD1,
- Thomas Norton, MD1,
- Andrea T Hooper, PhD1,
- Jennifer D Hamilton, PhD1,
- Cynthia Pan, BPharm1,
- Adnan Mahmood, MD1,
- Alina Baum, PhD1,
- Christos A Kyratsous, PhD1,
- Yunji Kim, PharmD1,
- Janie Parrino, MD1,
- Wendy Kampman, MD1,
- Lilia Roque-Guerrero, MD2,
- Roxana Stoici, MD3,
- Adil Fatakia, MD4,
- Yuhwen Soo, PhD1,
- Gregory P Geba, MD DrPH1,
- Bari Kowal, MS1,
- A Thomas DiCioccio, PhD1,
- Neil Stahl, PhD1,
- Leah Lipsich, PhD1,
- Ned Braunstein, MD1,
- Gary A Herman, MD1,
- George D Yancopoulos, MD1,
- David M Weinreich, MD1,
- Study Investigators*
- 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
- 2Bio-Medical Research, LLC, Miami, FL, USA
- 3Global Clinical Professionals Research, St. Petersburg, FL, USA
- 4Tandem Clinical Research, LLC, Marrero, LA, USA
- ↵*Corresponding author; email: cynthia.portalcelhay{at}regeneron.com
Posted November 10, 2021.
Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient setting
